References
1. Kaltseis J, Rainer J, De Hoog GS. Ecology of Pseudallescheria and
Scedosporium species in human-dominated and natural environments and
their distribution in clinical samples. Med Mycol . 2009;
47(4):398-405.
2. Rougeron A, Giraud S, Alastruey-Izquierdo A, et al. Ecology of
Scedosporium Species: Present Knowledge and Future Research.Mycopathologia . 2018; 183(1):185-200.
3. Liu W, Feng RZ, Jiang HL. Scedosporium spp lung infection in
immunocompetent patients: A systematic review and MOOSE-compliant
meta-analysis. Medicine (Baltimore) . 2019; 98(41):e17535.
4. Heath CH, Slavin MA, Sorrell TC, et al. Population-based surveillance
for scedosporiosis in Australia: epidemiology, disease manifestations
and emergence of Scedosporium aurantiacum infection. Clin
Microbiol Infect . 2009; 15(7):689-693.
5. Rodriguez-Tudela JL, Berenguer J, Guarro J, et al. Epidemiology and
outcome of Scedosporium prolificans infection, a review of 162 cases.Med Mycol . 2009; 47(4):359-370.
6. Grenouillet F, Botterel F, Crouzet J, et al. Scedosporium
prolificans: an emerging pathogen in France?. Med Mycol . 2009;
47(4):343-350.
7. Tintelnot K, Just-Nübling G, Horré R, et al. A review of German
Scedosporium prolificans cases from 1993 to 2007. Med Mycol .
2009; 47(4):351-358.
8. Ramirez-Garcia A, Pellon A, Rementeria A, et al. Scedosporium and
Lomentospora: an updated overview of underrated opportunists. Med
Mycol . 2018; 56(suppl_1):102-125.
9. Lamaris GA, Chamilos G, Lewis RE, et al. Scedosporium infection in a
tertiary care cancer center: a review of 25 cases from 1989-2006.Clin Infect Dis . 2006; 43(12):1580-1584.
10. Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and
uncommon medically important fungal pathogens. Clin Microbiol
Infect . 2004; 10(Suppl 1):48-66.
11. Cimon B, Carrère J, Vinatier JF, et al. Clinical significance of
Scedosporium apiospermum in patients with cystic fibrosis. Eur J
Clin Microbiol Infect Dis . 2000; 19(1):53-56.
12. Bashir G, Shakeel S, Wani T, et al. Pulmonary pseudallescheriasis in
a patient with healed tuberculosis. Mycopathologia . 2004;
158(3):289-291.
13. Tortorano AM, Richardson M, Roilides E, et al. ESCMID and ECMM joint
guidelines on diagnosis and management of hyalohyphomycosis: Fusarium
spp., Scedosporium spp. and others. Clin Microbiol Infect . 2014;
20(Suppl 3):27-46.
14. Tekavec J, Mlinarić-Missoni E, Babic-Vazic V. Pulmonary tuberculosis
associated with invasive pseudallescheriasis. Chest . 1997;
111(2):508-511.
15. Ogata H, Harada E, Okamoto I. Scedosporium apiospermum lung disease
in a patient with nontuberculous mycobacteria. Respirol Case Rep .
2020; 9(1):e00691.
16. Rathi M, Gundlapalli S, Ramachandran R, et al. A rare case of
Cytomegalovirus, Scedosporium apiospermum and Mycobacterium tuberculosis
in a renal transplant recipient. BMC Infect Dis . 2014; 14:259.
17. Guarro J, Kantarcioglu AS, Horré R, et al. Scedosporium apiospermum:
changing clinical spectrum of a therapy-refractory opportunist.Med Mycol . 2006; 44(4):295-327.
18. Cortez KJ, Roilides E, Quiroz-Telles F, Meletiadis J, Antachopoulos
C, Knudsen T, Buchanan W, Milanovich J, Sutton DA, Fothergill A, Rinaldi
MG, Shea YR, Zaoutis T, Kottilil S, Walsh TJ. Infections caused by
Scedosporium spp. Clin Microbiol Rev . 2008; 21(1):157-197.
19. Mir WAY, Shrestha DB, Khan Suheb MZ, et al. Scedosporium apiospermum
Pneumonia in an Immunocompetent Host. Cureus . 2021; 13(8):e16891.
20. Kim JS, Choi M, Nam CH, et al. Co-infection of Scedosporium
apiospermum and Mycobacterium chelonae in an immunocompetent host.J Dermatol . 2014; 41(10):922-925.
21. Sunagawa K, Yagoshi M, Suzuki A, et al. Cytological and molecular
detection of Scedosporium apiospermum in a patient treated for a
Mycobacterium avium complex infection. Diagn Cytopathol . 2018;
46(7):642-644.
22. Xiao W, Han P, Xu Z, et al. Pulmonary scedosporiosis in a patient
with acute hematopoietic failure: Diagnosis aided by next-generation
sequencing. Int J Infect Dis . 2019; 85:114-116.
23. Martin-Vicente A, Guarro J, González GM, et al. Voriconazole MICs
are predictive for the outcome of experimental disseminated
scedosporiosis. J Antimicrob Chemother . 2017; 72(4):1118-1122.
24. Lelièvre B, Legras P, Godon C, et al. Experimental models of
disseminated scedosporiosis with cerebral involvement. J Pharmacol
Exp Ther . 2013; 345(2):198-205.
25. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles
against Scedosporium spp. Antimicrob Agents Chemother . 2001;
45(7):2151-2153.
26. Solé A, García-Robles AA, Jordá C, et al. Salvage therapy with
topical posaconazole in lung transplant recipients with invasive
Scedosporium infection. Am J Transplant . 2018; 18(2):504-509.
27. Cuenca-Estrella M, Alastruey-Izquierdo A, Alcazar-Fuoli L, et al. In
vitro activities of 35 double combinations of antifungal agents against
Scedosporium apiospermum and Scedosporium prolificans. Antimicrob
Agents Chemother . 2008; 52(3):1136-1139.
28. Schwarz C, Brandt C, Melichar V, et al. Combined antifungal therapy
is superior to monotherapy in pulmonary scedosporiosis in cystic
fibrosis. J Cyst Fibros . 2019; 18(2):227-232.
29. Castanheira M, Duncanson FP, Diekema DJ, et al. Activities of E1210
and comparator agents tested by CLSI and EUCAST broth microdilution
methods against Fusarium and Scedosporium species identified using
molecular methods. Antimicrob Agents Chemother . 2012;
56(1):352-357.
30. Alkhazraji S, Gebremariam T, Alqarihi A, et al. Fosmanogepix
(APX001) Is Effective in the Treatment of Immunocompromised Mice
Infected with Invasive Pulmonary Scedosporiosis or Disseminated
Fusariosis. Antimicrob Agents Chemother . 2020; 64(3):e01735-19.
31. Oliver JD, Sibley GEM, Beckmann N, et al. F901318 represents a novel
class of antifungal drug that inhibits dihydroorotate dehydrogenase.Proc Natl Acad Sci U S A . 2016; 113(45):12809-12814.
32. Wiederhold NP, Patterson TF, Srinivasan A, et al. Repurposing
auranofin as an antifungal: In vitro activity against a variety of
medically important fungi. Virulence . 2017; 8(2):138-142.
33. Staerck C, Tabiasco J, Godon C, et al. Transcriptional profiling of
Scedosporium apiospermum enzymatic antioxidant gene battery unravels the
involvement of thioredoxin reductases against chemical and phagocytic
cells oxidative stress. Med Mycol . 2019; 57(3):363-373.